CHEK2 and breast cancer: Depending on family history (FH), the CHEK2 variant confers a lifetime BC risk (LTBCR, defined as the risk of developing BC from age 20 to 80) of 20–55 % [[1], [2], [3], [4], [5], [6], [7]], compared to the population-based BC risk of 14 % [8].